← Back to Search

Platinum-Based Chemotherapy

Arm II (non-squamous NSCLC) for Lung Cancer

Phase 2
Waitlist Available
Led By Conor E Steuer
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
No Placebo-Only Group

Summary

This trial is testing how well platinum-based chemotherapy works with durvalumab in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Eligible Conditions
  • Lung Cancer
  • Non-Small Cell Lung Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
6-months progression-free survival (PFS) rate
Secondary study objectives
Incidence of adverse events (AEs)
Overall survival (OS)
PFS

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm II (non-squamous NSCLC)Experimental Treatment3 Interventions
Patients receive carboplatin IV over 15-60 minutes, pemetrexed IV over 10 minutes and durvalumab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who do not progress receive durvalumab IV and pemetrexed IV every 3 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
Group II: Arm I (squamous NSCLC)Experimental Treatment3 Interventions
Patients receive carboplatin IV over 15-60 minutes, paclitaxel IV over 3 hours and durvalumab IV over 1 hour on day 1. Treatment repeats every 3 weeks for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who do not progress receive durvalumab IV every 4 weeks for up to 35 cycles in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pemetrexed
FDA approved
Paclitaxel
FDA approved
Carboplatin
FDA approved
Durvalumab
FDA approved

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,887 Previous Clinical Trials
41,021,028 Total Patients Enrolled
Emory UniversityLead Sponsor
1,691 Previous Clinical Trials
2,603,788 Total Patients Enrolled
Conor E SteuerPrincipal InvestigatorEmory University Hospital/Winship Cancer Institute
1 Previous Clinical Trials
50 Total Patients Enrolled
~0 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top